“Belgium’s participation to 1+Million genome initiative marks another step towards achieving access to reference genomic data for screening and personalised medicine in Europe.” the European Commission
The 1+Million Genomes Initiative is an european genomic initiative regrouping 24 countries aims “to access to at least 1 million sequenced genomes in the EU by 2022”.
This will fully leverage the potential of genomics in the prevention, diagnostics, and therapy of cancer, non-communicable diseases, rare diseases, and infectious diseases – for the benefit of our citizens and patients, health care systems, and research and innovation infrastructure.
On 26 August 2020, Belgium joined the project. Belgium’s participation marks yet another step towards achieving access to reference genomic data for screening and personalised medicine in Europe.
22 November 2022 (8.45-15.00) in Brussels
The Federated EGA is an infrastructure built upon the European Genome-phenome Archive (EGA), an EMBL-EBI and CRG data resource for secure archiving and sharing of human sensitive biomolecular and phenotypic data resulting from biomedical research projects. With technical tools for the deployment of nationally located secure database nodes and appropriate protocols to connect nodes across the federation for search and access requests, the system supports national data management requirements for genomic and clinical data collected from citizens as part of healthcare or biomedical research projects. Under the European COVID-19 Data Platform, the Federated EGA is being built out rapidly to support COVID-19 host biomolecular studies across Europe.
The GISAID Initiative promotes the rapid sharing of data from all influenza viruses and the coronavirus causing COVID-19. This includes genetic sequence and related clinical and epidemiological data associated with human viruses, and geographical as well as species-specific data associated with avian and other animal viruses, to help researchers understand how viruses evolve and spread during epidemics and pandemics.